GTBP · GT Biopharma, Inc.
$0.30
-0.02 (-5.20%)
At close · Aug 6
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s December 31, 2025, financial statements, raised substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$10.85M
Shares
36.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.30
Open$0.32
Day$0.30–0.32
52W$0.26–1.89
Avg vol 30d795K
Short int4.8M · 13.3% float · 4.2d
Short vol51%
Last earningsJun 30, 2021
DataJan 2020–Aug 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−26%
below
RSI (14)
38
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−33%
trailing
6-month return
−36%
trailing
YTD return
−62%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
22 of 42 funds reported for Jun 30 · net +280.3K sh shares · +8 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.27% of float · ▲ +39.7% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
42 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
EPS growth
+4%
Y/Y
Free cash flow
$-12.9M
Balance sheet
$6.8M
net cash
Quant / Vol
risk profile
Volatility
126%
annualized · 1-yr
Max drawdown
−85%
past year
ATR
11.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
38
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
22 of 42 funds reported for Jun 30 · net +280.3K sh shares · +8 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.27% of float · ▲ +39.7% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
42 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $2
vs 200-day avg -42%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTBP
this stock
GT Biopharma, Inc.
|
$10.85M | -61.7% | — | — | 13.3% |
|
ONC
BeOne Medicines Ltd.
|
$487.49B | +8.6% | +22179.2% | 749.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.68B | +6.8% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.49B | +0.3% | +20.8% | 19.1 | 3.4% |
|
ARGX
Argenx SE
|
$54.76B | +4.1% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTBP | -2.3% | -32.7% | -36.1% | +2.4% | -61.7% |
| SPY | +3.6% | +2.2% | +12.8% | +2.9% | +12.7% |
| vs SPY | -5.9% | -34.9% | -48.9% | -0.5% | -74.4% |
Key facts
CIK
109657
CUSIP
36254L308
13F (30d)
20 filings
20 filers
Visit website
Investor relations